Eligibility For CCM® Therapy
Ejection Fraction 25-45%
Class III Heart Failure
Guideline Directed Medical Therapy
Not indicated for Cardiac Resynchronization Therapy
Optimizer® Smart with CCM® Therapy: A Revolutionary Approach
The Optimizer® Smart, a minimally invasive, implantable device, is the first therapy of its kind designed to strengthen the heart so it can contract more forcibly, allowing more oxygen-rich blood to reach the body.
Studies evaluating the FDA-approved therapy have demonstrated the device is safe, and improves overall heart function, and quality of life for patients.3
CCM® therapy sends precisely timed electrical pulses to the heart cells during the absolute refractory period of the beating cycle, just after the heart contracts, to improve systolic contraction of the heart.
The Optimizer® Smart was granted Breakthrough Device designation by the FDA, and it is the first and only FDA-approved (March 2019) device in the United States, or elsewhere in the world, for the delivery of CCM® therapy.
HOPE IS HERE
“CCM® therapy has given me my life back. I can’t even call it an impact, it’s literally given me my life back.”
“I’m pretty much back to all my normal duties around the barn. I think that the benefit you get from that gives you such a better outlook on life, and just continues to get better all the time.”
“Now, I can go to football games and watch my son coach. My three youngest grandchildren, we’re going to go to Disney World and enjoy our time together – which is all I live for.”
Have Improved NYHA Heart Failure Status by Greater Than or Equal to 1 Class
Who is Impulse Dynamics?
Impulse Dynamics is a medical device company determined to transform the treatment of chronic heart failure. We are professionally directed by an expert team of world-renowned scientists, engineers, physicians, and business executives. Our research and commercial operations across the globe include corporate headquarters in the United States (Marlton, NJ), the Netherlands Antilles, Germany, and Hong Kong. We conduct research in major universities and hospitals worldwide where we are currently engaged in clinical trials both in the United States and Europe. Our company was incorporated on May 11, 1998 as a subsidiary of the Hobart Group under the guidance our founder, Professor Shlomo Ben-Haim. With qualifications in medicine, biophysics, nuclearphysics, mathematics, and philosophy, Ben-Haim is a luminary figure both in medicine and across the life sciences industry. He is a relentlessly prolific researcher and inventor with more than 550 patents to his name. Among his many notable achievements is the foundational navigated cardiac catheterization technology that enables Biosense-Webster’s CARTO EP navigation system.
About CCM® Therapy
Impulse Dynamics offers cardiac contractility modulation therapy to treat adults with moderate-to-severe chronic heart failure. CCM® delivers non-excitatory electrical signals to the right side of the intraventricular septum during the absolute refractory period of the ventricular contraction, and does not trigger a new action potential. CCM® signals are delivered by Impulse Dynamics’ Optimizer system (i.e. Optimizer IVs), which is an implantable pulse generator. This device is implanted in a minimally-invasive procedure under local anesthesia, typically in the right pectoral region. CCM® has been evaluated in patients with heart failure with reduced ejection fraction (HFrEF) In contrast to a pacemaker or a defibrillator, the system is designed to modulate the strength of contraction of the heart muscle rather than the rhythm. CCM® therapy is delivered at regular intervals throughout the day.
FDA Breakthrough Designation
FDA Approval – Post Market Approval
First commercial implant (Ohio State University)
FDA Approval of Optimizer® two-lead system
Transitional Pass-Through Payment Status for Outpatient Prospective Payment System January 2020
Applied for NTAP New Technology Add-on Payment for Inpatient Prospective Payment System 2021, to be effective October 1, 2020 if granted
Clinical trials have demonstrated statistically significant and clinically meaningful improvements in the FIX-HF-5C randomized trial:
- CCM® subjects improved 11.7 points in the MLWHFQ score compared to the control group
- CCM® subjects improved their NYHA heart failure status by >1 class 81% of the time compared to 42% in the control group
- CCM® subjects walked on average 33.7 meters further than the control group during the 6-minute hall walk test
Score change in the MLWHFQ
Improved NYHA heart failure status by greater than 1 Class
meters further than control group for 6-minute hall walk test
We have pathways to payment with Medicare and commercial payors in multiple care settings – inpatient, outpatient and surgery centers. Additionally, we have a range of resources available for facilities, practitioners and patients related to obtaining access to Optimizer®. Impulse Dynamics has committed ourselves to maximizing availability of Cardiac Contractility Modulation to patients who would benefit from it.
Impulse Dynamics has committed ourselves to maximizing availability of Cardiac Contractility Modulation to patients who would benefit from it. To learn more, please contact your local Impulse Dynamics Territory Manager or email firstname.lastname@example.org
What Providers are saying about Optimzer® Smart Therapy
“I see probably in the neighborhood of 20-25 patients a month who would benefit from CCM® Therapy, specifically.”
“The FDA granted breakthrough designation to this device and the reason they did that is because this is the first device-based therapy in this population that can reduce symptoms when medications alone are not enough.”
“I’ve been amazed at how virtually every single one of my patients has seen a transformation in their life, having received this therapy.”
“I think if you’re feeling that you have run out of options for the treatment of your heart failure and you haven’t had a conversation with a cardiologist or an electrophysiologist about the role of CCM®, then I think that there are still potential options for you, and you really aren’t at the end of the road.”